Madrigal Pharmaceuticals Inc (MDGL) FinancialsMDGLMadrigal Pharmaceuticals Inc

Evaluating the bottom line, Madrigal Pharmaceuticals, Inc. maintains a gross margin of 89.02%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -15.46%, while the net margin is -15.91%. These profitability ratios, combined with a Return on Equity (ROE) of -53.31%, provide a clear picture of how effectively MDGL converts its operational activities into shareholder value.

In the context of the broader market, MDGL competes directly with industry leaders such as RGEN and IBRX. With a market capitalization of $11.27B, it holds a leading position in the sector. When comparing efficiency, MDGL's gross margin of 89.02% stands against RGEN's 53.91% and IBRX's 99.42%. Such benchmarking helps identify whether Madrigal Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Madrigal's revenue has shown strong growth, with Q2 2026 revenue at $364.3 million, up 71% year-over-year. However, the company is still operating at a loss, with a net income of -57.939 million in Q2 2026 and a gross margin of 89.02%.